The first new weight-loss drugs in more than a decade are now on pharmacists' shelves. Will these medications provide the solution many overweight women are seeking? The September 2012 issue of Harvard Women's Health Watch looks at the benefits—and risks—of both new and established weight-loss drugs.
In June, the FDA approved lorcaserin (Belviq). It suppresses hunger by stimulating a receptor serotonin, a chemical messenger in the brain that regulates fullness and metabolism. A month later, the FDA approved Qsymia, a combination of phentermine and the antiseizure/antimigraine drug topiramate. Qsymia also suppresses appetite, and it appears to be more effective for weight loss than any other single drug.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.